Find a Clinical Trial
The clinical trials at Gundersen offer the same cutting-edge treatments as those at other top medical research hospitals – and often much sooner than they’re available to everyone.
Showing 10 of 89 trials
NCI-2020-01256
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Older adult (65+)
CCTG MA.39
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Adult (18-64)
Older adult (65+)
NCI-2021-09851
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Adult (18-64)
Older adult (65+)
TP-CA-002
GEMINI-NSCLC: NSCLC Biomarker Study
Adult (18-64)
Older adult (65+)
NCI-2017-01017
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Adult (18-64)
Older adult (65+)
NCI-2022-07304
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
Adult (18-64)
Older adult (65+)
NCI-2020-05659
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Adult (18-64)
Older adult (65+)
NCI-2022-10845
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Child (birth - 17)
Adult (18-64)
NCI-2022-07535
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Adult (18-64)
NCI-2022-06841
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Adult (18-64)
Older adult (65+)